Fatty Liver Increases the Association of Metabolic Syndrome With Diabetes and Atherosclerosis
- Juan G. Juárez-Rojas, PHD1,
- Aida X. Medina-Urrutia, MSC1,
- Esteban Jorge-Galarza, MSC1,
- Carmen González-Salazar, RD1,
- Eric Kimura-Hayama, MD2,
- Guillermo Cardoso-Saldaña, PHD1,
- Rosalinda Posadas-Sánchez, MSC1,
- Rocio Martínez-Alvarado, MD1 and
- Carlos Posadas-Romero, MD1⇓
- 1Department of Endocrinology, National Institute of Cardiology “Ignacio Chávez,” Mexico City, Mexico
- 2Division of Computed Tomography, Department of Radiology, National Institute of Cardiology “Ignacio Chávez,” Mexico City, Mexico
- Corresponding author: Carlos Posadas-Romero, .
OBJECTIVE To analyze the participation of fatty liver (FL) in the association of metabolic syndrome (MS) with type 2 diabetes and coronary artery calcification (CAC).
RESEARCH DESIGN AND METHODS A total of 765 subjects (52% women) aged 30 to 75 years without clinical atherosclerosis were included in this study. MS was defined in accordance with the Adult Treatment Panel III (ATPIII) guidelines, while FL and CAC were identified by computed tomography.
RESULTS There were increasing frequencies of type 2 diabetes and CAC in all three groups: control, MS without FL, and MS plus FL. Multivariable-adjusted logistic regression analyses showed that FL increased the association of MS with type 2 diabetes in both women [odds ratio 10.6 (95% CI 3.4–33.7)] and men [12.1 (4.1–36.1)]. In women, FL also increased the association of MS with CAC [2.34 (1.07–5.12)].
CONCLUSIONS FL increases the association of MS with type 2 diabetes and subclinical atherosclerosis.
- Received June 29, 2012.
- Accepted November 8, 2012.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.